Rahul Jain's on 6 large & midcap IT stocks to bet on, explains what's driving sectoral outperformance
Rahul Jain, Director, Dolat Capital, favours LTIM due to its order book growth and potential stability following a CEO change, anticipating a return to pre-Covid growth levels. HCL Tech's consistent outlook and Infosys' potential guidance increase also make them attractive. In the midcap space, Mphasis, KPIT, and eClerx are favored for their growth potential relative to valuation.
ADVERTISEMENT We have seen Nifty IT outperforming the rest of the market this month. What is driving this sudden strength? Is it just pure sector rotation? Is it the churn that we are seeing or do you believe fundamentally this has merit in terms of the way Nifty IT has been outperforming?
Rahul Jain: A part of this could be related to the kind of correction that we saw in the February-March period when the expectation for the sector in terms of growth in earnings were much higher and subsequently the valuation corrected. When the earnings started, we got a mixed set of commentary where some companies saw a lot of impact related to the macro or the tariff kind of a thing, while many other companies said that they have seen very limited observation in terms of any deterioration related to that.
Since the earnings, one-and-a-half, two months have gone and we have not seen any further deterioration, rather on the tariff side, there is a lot of normalisation that has happened with many countries. Some bit of ambiguity will come into play as tariffs eventually come into picture. But for now, no bad news has acted as good news in the space. Valuations were low, growth expectations are low, and valuation can see some room for upside if the growth eventually improves.
The market is anticipating that as the year progresses and there is no incremental bad news shaping up in the sector. The growth assumption in the sector will eventually improve and will drive the valuation. So, that is something which is finding value in this space at this point and should continue as the year progresses.
The valuation comfort is still there, but also gives us some sense how the deal momentum is picking up. Is there anything incremental that you are picking up right now because back in the earning season, we have seen quite a mixed commentary coming in especially with respect to discretionary spending in the US. Has anything changed in terms of the pickup over there?
Rahul Jain: We keep getting those press releases by the respective companies where they announce important deals once in a while, so that is a usual activity. But we do not hear from our recent interaction with companies where they are seeing the stalling of the ramp up. Stalling of the ramp up has been a bigger pain point in the last two years, more than the deal gaps itself. I agree that the deal win momentum is quite mixed across players and it is not very uniform. But we could also see that there was a lot of ambiguity in the mind of the spenders also in that period. Now those things are getting streamlined to some degree and may happen more in Q1 as tariffs eventually take into action. Then probably there could be an opportunity of pent-up demand coming starting from Q2, Q3 onwards.
ADVERTISEMENT There is also one very big trend on the Gen-AI side where the adoption is coming closer on, the timeline point of view, which itself could also be another round of trigger for tier I vendors to begin with in India. Those are the two triggers pending and whether they happen after Q1 or later in the year, is something that we need to work on. So far with the expectation coming into play, so far giving the opportunity that is available to us, we are in the bottom part and we would only see things improving here on. What is your sense on how much the AI disruption is already in the price or how much of it is yet to be seen because it is such an evolving landscape out there?
Rahul Jain: It is very difficult to measure it in a very precise manner, but going by the past cycle of various technology trends that has always been perceived as a risk to the sector. So we have seen that when there was too much talk around blockchain in digital or many other technology trends in the early stage of adoption, there are a lot of boutique companies which play roles which are very tech savvy, very individual led, smaller setup, doing pilots for a lot of companies.
ADVERTISEMENT But once these global enterprises decide that they need a mass rollout, and scale this technology enterprise wide, then their key support vendors are the same top 10 companies. So, when the mass deployment of those technologies has to happen, they eventually rely on the likes of Accenture, TCS, Infosys, and the like. I think that is what will happen with AI also eventually. Are we six months away from that trend? Are we one-year away from the trend? We do not know. But the smartest people on the AI side talk about how we will see mega adoption within 12 to 24 months. Some of that early trend could happen in the next six months and it may scale up 18 months from now based on those understanding, but it is very difficult for any one of us to single out that this is when there will be a big shift.
ADVERTISEMENT Even when we are talking about the entire outperformance in the Nifty IT space, there is one basket in particular that is midcap IT which has outperformed the overall basket. Do you still see valuation comfort over here? If you had to place your bets in the entire IT space, would the midcaps be making it to your radar?
Rahul Jain: The whole logic of why IT midcap has been doing so well for so long over tier I names is the sheer difference in the growth rate of these companies and these companies are growing anywhere between 12% and 18% on organic basis and in some cases, there is inorganic element as well. While the largecaps are at a very reasonable valuation, their growth in the last three-five years except for one year in between because of Covid – their 10-year CAGR – is in that high single to mid-single digit basis. So, for a lot of companies, the filtration of investment would only come if the growth can compound in early double digits at least and that is the reason people are seeing more value in stories that can become large and can grow faster. So, the likes of Persistent, Coforce, KPITs – which are reasonable in terms of size with close to $500 million to $2 billion revenue band, are behaving like larger midcaps. They are not midcap or tier II as such, they are good in size on their own and where there is a lot of money can be deployed. So, those are the areas where people are parking money because of the growth rate differential.
ADVERTISEMENT Over a period of time, once the growth differential is also narrow, the valuation differential will narrow as well. That is something we are waiting for. Once we see a better IT cycle, the growth differential will narrow. In a troubled environment that we have seen in the last two, two-and-a-half years, companies with much higher execution and much smaller size become an advantage and that is what we have seen in some companies. While a largecap does take a hit because of the macro spending factors, that explains why that differentiation has happened.
Would you elaborate on that? What is your pecking order in terms of your preferred list from within it?
Rahul Jain: There are three-four names which we like and these have a lot of short-term as well as long-term reasoning behind. Within the larger caps, we like LTIM. Here the order book growth has been decent on the closing basis of FY25 and a CEO change can probably bring in some kind of stability on the top layer which has seen some attrition in the last 12-18 months. That is something which we like and the companies historically pre-Covid also have been doing better in terms of growth versus the tier I peers. So, it is where a large business which can do well and is reporting below its potential for the last two-three years, has good potential to do better from here on. So, that is one largecap name that we like. We also like HCL Tech given its consistent, decent confident outlook for this year and we also see potential for Infosys to gradually scale up its guidance later in the year.
These are the two-three names that we like in the tier I pack. Other largecap companies we like less. On the midcap side, some of the good businesses are very expensively priced. So, leaving those aside, right now we like Mphasis, KPIT, eClerx. These are some of the companies where growth versus valuation provides an opportunity to make money even from this point. So, these are the names that we are liking within the mid-tier to smallcap.
(You can now subscribe to our ETMarkets WhatsApp channel)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
3 hours ago
- Time of India
India a 'bright spot' amid global uncertainty, says Chief Economic Advisor V Anantha Nageswaran
India remains a rare "bright spot" in a world facing growing uncertainty, said Chief Economic Advisor (CEA) V Anantha Nageswaran , pointing to the country's steady economic performance despite ongoing global challenges. Talking to PTI, the CEA said that while conflicts and disruptions have been part of the global scene since 2022, they have become more intense and unpredictable, making the overall environment--whether political, economic or security-related--far more difficult for growth across the world. "You could say that downside risks are higher than the potential for upside surprises," Nageswaran said, when asked for his views on the impact on the Indian economy due to rising global uncertainties caused by military conflicts in West Asia, between Ukraine and Russia, and also between India and Pakistan, as well as tariff wars. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like $50/Night for a 5-Star Hotel? This Secret Booking Trick Will Shock You! Liseer Read More Undo He said this is not just a problem for India -- it's affecting many countries. "To some extent, one can say that the global environment today--whether political, economic or related to security--has become considerably more complicated and more challenging for growth, not just for India but for several countries, almost for the entire world economy," the CEA said. Live Events But under these circumstances, Nageswaran said he believes that India does indeed stand out as a relatively "bright spot." Noting that India's economy has shown resilience since the COVID-19 pandemic, achieving strong growth while also improving its fiscal health, he said, "We have reduced the fiscal deficit and brought down government debt levels ." According to him, this has helped build confidence among investors, as reflected in the narrowing gap between Indian and US 10-year government bond yields-- "something we've never seen at this level before." The CEA said India's current growth of around 6.5 per cent is a significant achievement under the circumstances. Given how tough the global climate has become since the 2008 financial crisis, maintaining this rate is no small feat, he said. While the government continues efforts to raise the growth rate to 7 per cent and beyond, Nageswaran cautioned that the world is no longer operating under the same favourable conditions it once did. The CEA said that the government is doing the hard work to grow faster, but even maintaining a 6.5 per cent growth rate was a solid outcome in today's world.


Time of India
3 hours ago
- Time of India
Advantage India! As West moves away from China & Bangladesh, India's apparel exports see big growth; $120 billion US market biggest opportunity
Buyers from developed countries are encouraging Indian manufacturers to increase production capacity. (AI image) India is fast emerging as an alternate destination for reliable apparel sourcing for buyers in the West, as they move away from Bangladesh and China. India's garment exports maintained robust growth, showing an 11.3% year-on-year increase in May, according to data from the Confederation of Indian Textile Industry (CITI). This export growth provides relief to India's apparel sector, which experienced two consecutive years of difficulties following the pandemic. In the US market, India's share stands at $10 billion, whilst China maintains a $30 billion share. Buyers from developed countries are encouraging Indian manufacturers to increase production capacity and obtain necessary certifications. This push comes as India stands to benefit from duty advantages over China, resulting from reciprocal tariffs implemented during the Donald Trump administration. Advantage India The sector witnessed significant growth following political instability after Sheikh Hasina's government was removed in Bangladesh last August, according to an ET report. Export figures rose by 17.3% in September, followed by a 24.35% increase in October. Also Read | 'Dramatic decline…watch out…': China's exports to US dip sharply amid Trump trade war; why India needs to be on the guard "There was a fall in India's apparel exports after Covid, as consumers bought fewer newer clothes due to excess purchases made during the Covid period. There was a period of stagnation or degrowth for about two years post Covid," said Sanjay K Jain, chairman, National Textile Committee, Indian Chamber of Commerce. The apparel sector began showing signs of improvement after the political changes and unrest in Bangladesh. Industry experts noted that due to the continuous nature of apparel production, buyers seek stability in their supply chains. Bangladesh's apparel sector has substantial manufacturing capabilities, enabling them to fulfil large orders quickly, which differs from Indian manufacturers. Also Read | Big win! China companies now exporting 'Made in India' smartphones & electronics to US, West Asia; notable shift for Chinese brands The export growth is expected to continue for Indian manufacturers due to duty advantages compared to China. "There is a big window of opportunity for Indian apparel exporters. The $120 billion US market is the biggest opportunity. All we need is to get the raw material at competitive rates," said Jain. Whilst apparel exports continue to rise, raw cotton imports are increasing as domestic prices exceed international rates. The projected cotton imports for India in 2024-25 are set to more than double compared to the previous year. The Cotton Association of India reports that the nation's cotton imports are expected to reach 3.3 million bales of 170 kilograms each in 2024-25, an increase from 1.52 million bales in the previous year. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Mint
3 hours ago
- Mint
Stent maker SMT set for ₹2,000 crore IPO; draft filing next month, bankers onboard
MUMBAI : Sahajanand Medical Technologies (SMT), a leading domestic manufacturer of cardiac stents, is set to file its draft papers with market regulator Sebi next month for a planned ₹1,500-2,000 crore initial public offering (IPO), two people aware of the development told Mint. The IPO is being led by Motilal Oswal, Avendus, Nuvama and HSBC, and will see existing investors such as Samara Capital, Kotak, and Morgan Stanley offloading their stakes, one of the people cited above said. 'The issue will have only an offer-for-sale component and the draft papers are expected to be filed in July with a potential listing by the end of this year," the second person said. This means that the IPO will not raise any fresh capital for SMT and all proceeds from the share sale will go only to the selling shareholders. While Avendus, HSBC and SMT declined to comment, others did not immediately respond to Mint's requests. The first attempt This would mark SMT's second attempt to go public after it shelved a 2021 IPO plan. SMT first filed for an IPO in September 2021 with plans to raise around ₹1,500 crore, comprising both an OFS and a primary issue. The funds were earmarked for repaying debt and supporting the working capital needs of its foreign subsidiary, Vascular Innovations. The IPO was later put on hold. Instead, SMT raised around ₹170 crore from Kotak's Pre-IPO Opportunities Fund in 2023, which valued the company at approximately ₹3,000 crore. Also read: GIC-backed Asia Healthcare Holdings to acquire Dr Dangs Labs Financials and growth Since then, SMT has posted notable growth. It recorded revenue of ₹909 crore in FY24, up from ₹588 crore in FY21. Losses narrowed to ₹7.4 crore in FY24 from ₹72.38 crore in FY21. The company also posted a profit of ₹11.9 crore in FY23 on revenue of ₹801 crore, according to data from Tracxn. 'With better financials, the company's valuation has also improved, and the selling shareholders are expected to make big gains from the IPO if all goes as planned," one of the people added. SMT was incorporated in 1998 by Dhirajlal Kotadia and family. It develops invasive cardiovascular devices such as coronary, structural heart and closure occluder products. The company has made several acquisitions including Imex SC, Zarek and Vascular Concepts Ltd, which expanded its distribution network and product portfolio. The company recently reshuffled its leadership when it appointed Bhargav Kotadia, part of the founding family, as the chief executive office, earlier this year, replacing Ganesh Sabat. Other appointments include Jose Calle Gordo as the chairman, while Dhirajlal Kotadia will transition to chairman emeritus and continue to provide strategic guidance, according to a company release in February. As of July 2024, Samara Capital Markets Holding Ltd and NHPEA Sparks Holdings BV—a Morgan Stanley subsidiary—held 31.4% and 16.2% stakes, respectively, as per a Crisil report. Kotak's pre-IPO fund held another 6%, while the rest was owned by promoters. SMT competes with global players like Abbott, Medtronic and Meril, as well as domestic rivals such as Healthium Medtech and Translumina Therapeutics. It holds around 25-30% market share in India's drug-eluting stent (DES) segment. Crisil noted SMT's wide distribution, better collections and market presence but flagged concerns around its large working capital needs, R&D-linked volatility in margins, and regulatory exposure. Also read: Healthcare investor Quadria raises $1.1 billion for Fund III, exceeds target Sector outlook India's cardiovascular device market, valued at $200 million in 2023, is expected to grow at a compounded annual growth rate (CAGR) of 14-15% over the next decade, Avendus said in a report. Regulatory price caps and broader inclusion of stent implants under government schemes have helped increase adoption. Domestic players' market share has risen from 35% to 60%, as global companies adjusted to lower pricing while Indian firms leveraged cost-effective manufacturing. Avendus also highlighted rising insurance coverage, affordability, and an expanding patient base as key growth drivers. Also read: The IPO buzz is back: These titans might go public in 2025